Aβ production and clearance by protein kinase C

David J. Hinton, Taylor L. Jacobson, Chelsea A. Adams, Doo Sup Choi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Alzheimer's disease is the most common form of dementia in the elderly population. One of the most notable pathological characteristics of Alzheimer's disease is the aggregation of amyloid β-peptide (Aβ) plaque from the processing of amyloid precursor protein (APP) in neurons, which leads to neurodegeneration and cognitive dysfunction. Recently, numerous studies suggest that activation of protein kinase C (PKC) reduces the production of Aβ plaque by promoting α-secretase activity, which is the enzyme that converts APP to the secretory form of amyloid precursor protein (sAPPβ). One isoform of PKC, PKCβ, is known to actively play a role in the clearance of Aβ plaque by activating endothelin converting enzyme type 1 (ECE-1), which can degrade Aβ plaque. Therefore, PKC can activate α-secretase and ECE-1 to limit the production of, and actively degrade, Aβ plaque, respectively. Here we discuss in more detail the various roles that PKC can have in Aβ plaque production and clearance and its implication in Alzheimer's disease. Moreover, PKC is a downstream signaling molecule of G-protein coupled receptors (GPCRs), which have also recently been shown to be implicated in the pathogenesis of Alzheimer's disease. Therefore, recent research efforts suggest that further investigation on the pharmacological regulation of PKC, possibly via GPCRs, may lead to the identification of clinically useful targets to treat Alzheimer's disease.

Original languageEnglish (US)
Title of host publicationResearch Progress in Alzheimer's Disease and Dementia (V)
PublisherNova Science Publishers, Inc.
Pages199-214
Number of pages16
ISBN (Print)9781619421929
StatePublished - 2012

Fingerprint

Protein Kinase C
Alzheimer Disease
Amyloid beta-Protein Precursor
Amyloid Precursor Protein Secretases
G-Protein-Coupled Receptors
Amyloid
Dementia
Protein Isoforms
Pharmacology
Neurons
Enzymes
Research
Population
Endothelin-Converting Enzymes

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Hinton, D. J., Jacobson, T. L., Adams, C. A., & Choi, D. S. (2012). Aβ production and clearance by protein kinase C. In Research Progress in Alzheimer's Disease and Dementia (V) (pp. 199-214). Nova Science Publishers, Inc..

Aβ production and clearance by protein kinase C. / Hinton, David J.; Jacobson, Taylor L.; Adams, Chelsea A.; Choi, Doo Sup.

Research Progress in Alzheimer's Disease and Dementia (V). Nova Science Publishers, Inc., 2012. p. 199-214.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hinton, DJ, Jacobson, TL, Adams, CA & Choi, DS 2012, Aβ production and clearance by protein kinase C. in Research Progress in Alzheimer's Disease and Dementia (V). Nova Science Publishers, Inc., pp. 199-214.
Hinton DJ, Jacobson TL, Adams CA, Choi DS. Aβ production and clearance by protein kinase C. In Research Progress in Alzheimer's Disease and Dementia (V). Nova Science Publishers, Inc. 2012. p. 199-214
Hinton, David J. ; Jacobson, Taylor L. ; Adams, Chelsea A. ; Choi, Doo Sup. / Aβ production and clearance by protein kinase C. Research Progress in Alzheimer's Disease and Dementia (V). Nova Science Publishers, Inc., 2012. pp. 199-214
@inbook{c66a2ae21b0541049130bbf90b07e4be,
title = "Aβ production and clearance by protein kinase C",
abstract = "Alzheimer's disease is the most common form of dementia in the elderly population. One of the most notable pathological characteristics of Alzheimer's disease is the aggregation of amyloid β-peptide (Aβ) plaque from the processing of amyloid precursor protein (APP) in neurons, which leads to neurodegeneration and cognitive dysfunction. Recently, numerous studies suggest that activation of protein kinase C (PKC) reduces the production of Aβ plaque by promoting α-secretase activity, which is the enzyme that converts APP to the secretory form of amyloid precursor protein (sAPPβ). One isoform of PKC, PKCβ, is known to actively play a role in the clearance of Aβ plaque by activating endothelin converting enzyme type 1 (ECE-1), which can degrade Aβ plaque. Therefore, PKC can activate α-secretase and ECE-1 to limit the production of, and actively degrade, Aβ plaque, respectively. Here we discuss in more detail the various roles that PKC can have in Aβ plaque production and clearance and its implication in Alzheimer's disease. Moreover, PKC is a downstream signaling molecule of G-protein coupled receptors (GPCRs), which have also recently been shown to be implicated in the pathogenesis of Alzheimer's disease. Therefore, recent research efforts suggest that further investigation on the pharmacological regulation of PKC, possibly via GPCRs, may lead to the identification of clinically useful targets to treat Alzheimer's disease.",
author = "Hinton, {David J.} and Jacobson, {Taylor L.} and Adams, {Chelsea A.} and Choi, {Doo Sup}",
year = "2012",
language = "English (US)",
isbn = "9781619421929",
pages = "199--214",
booktitle = "Research Progress in Alzheimer's Disease and Dementia (V)",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Aβ production and clearance by protein kinase C

AU - Hinton, David J.

AU - Jacobson, Taylor L.

AU - Adams, Chelsea A.

AU - Choi, Doo Sup

PY - 2012

Y1 - 2012

N2 - Alzheimer's disease is the most common form of dementia in the elderly population. One of the most notable pathological characteristics of Alzheimer's disease is the aggregation of amyloid β-peptide (Aβ) plaque from the processing of amyloid precursor protein (APP) in neurons, which leads to neurodegeneration and cognitive dysfunction. Recently, numerous studies suggest that activation of protein kinase C (PKC) reduces the production of Aβ plaque by promoting α-secretase activity, which is the enzyme that converts APP to the secretory form of amyloid precursor protein (sAPPβ). One isoform of PKC, PKCβ, is known to actively play a role in the clearance of Aβ plaque by activating endothelin converting enzyme type 1 (ECE-1), which can degrade Aβ plaque. Therefore, PKC can activate α-secretase and ECE-1 to limit the production of, and actively degrade, Aβ plaque, respectively. Here we discuss in more detail the various roles that PKC can have in Aβ plaque production and clearance and its implication in Alzheimer's disease. Moreover, PKC is a downstream signaling molecule of G-protein coupled receptors (GPCRs), which have also recently been shown to be implicated in the pathogenesis of Alzheimer's disease. Therefore, recent research efforts suggest that further investigation on the pharmacological regulation of PKC, possibly via GPCRs, may lead to the identification of clinically useful targets to treat Alzheimer's disease.

AB - Alzheimer's disease is the most common form of dementia in the elderly population. One of the most notable pathological characteristics of Alzheimer's disease is the aggregation of amyloid β-peptide (Aβ) plaque from the processing of amyloid precursor protein (APP) in neurons, which leads to neurodegeneration and cognitive dysfunction. Recently, numerous studies suggest that activation of protein kinase C (PKC) reduces the production of Aβ plaque by promoting α-secretase activity, which is the enzyme that converts APP to the secretory form of amyloid precursor protein (sAPPβ). One isoform of PKC, PKCβ, is known to actively play a role in the clearance of Aβ plaque by activating endothelin converting enzyme type 1 (ECE-1), which can degrade Aβ plaque. Therefore, PKC can activate α-secretase and ECE-1 to limit the production of, and actively degrade, Aβ plaque, respectively. Here we discuss in more detail the various roles that PKC can have in Aβ plaque production and clearance and its implication in Alzheimer's disease. Moreover, PKC is a downstream signaling molecule of G-protein coupled receptors (GPCRs), which have also recently been shown to be implicated in the pathogenesis of Alzheimer's disease. Therefore, recent research efforts suggest that further investigation on the pharmacological regulation of PKC, possibly via GPCRs, may lead to the identification of clinically useful targets to treat Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=84895212404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895212404&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84895212404

SN - 9781619421929

SP - 199

EP - 214

BT - Research Progress in Alzheimer's Disease and Dementia (V)

PB - Nova Science Publishers, Inc.

ER -